Biotech

Chinese animal gene modifier set to close $79m funding

Biocytogen delivers gene-modified mice to speed up development in the pharmaceutical industry. Riding the momentum of biotech development in China, the firm expects to IPO within three years.

Chinese gene-modified animal provider Biocytogen is going to close its Series D funding of $79 million on July 23, with four investors and a management team participating.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media